ClinicalTrials.gg

Atrial Fibrillation clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 4,016 studies for Atrial Fibrillation across more than 10 countries. 964 are recruiting or about to start. 3,433 of them are mainly about Atrial Fibrillation (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 4,229 studies for Atrial Fibrillation. How that becomes 4,009 here

This page counts the studies the registry files under Atrial Fibrillation, and those it files under no condition that list Atrial Fibrillationthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 4,229Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −67List Atrial Fibrillation as a condition, but the registry did not file them under itMost often written as “Atrial Fibrillation Rapid” (11), “Non-valvular Atrial Fibrillation (NVAF)” (10), and “Non-valvular Atrial Fibrillation” (8). The registry filed them under other conditions only, most often Stroke (12) and Heart Failure (11).
  3. −153Match it another way141 name it in the title, 8 in a keyword, and 4 by a synonym or other text the search reads.
  4. 4,009The count on this page166 of them list Atrial Fibrillation in their own words; the registry filed them under no condition.

Status

Completed
1,892
Recruiting
610
Status unknown
573
Not yet recruiting
305
Terminated
244
Active, not recruiting
222

Phase

Phase 4
365
Phase 3
270
Phase 2
178
Phase 1
55
Early Phase 1
10

Where

United States
993
Germany
417
China
376
Canada
318
France
317
United Kingdom
307

Who develops what

Add Atrial Fibrillation to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 10 companies, 13 with this as their studies’ main aim; 3 with a live phase 3 study; 4 primary completions in the next 12 months. Compare HK inno.N, Novartis and Regeneron Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
apixabanRecent, repeated
Evidence
  • NCT07626411 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Apixaban” · registered May 2026
  • NCT07175428 · Regeneron Pharmaceuticals · Phase 2 · live · comparator · “Apixaban” · registered Sep 2025
  • NCT05643573 · Bayer · Phase 3 · comparator · “Apixaban” · registered Nov 2022
  • NCT04218266 · Bayer · Phase 2 · comparator · “Apixaban” · registered Jan 2020
  • NCT03398434 · Novartis · Phase 2 · comparator · “Apixaban” · registered Jan 2018
Bristol-Myers Squibb59% of its industry studiesUS: off-patent, 1 generic marketedEU: off-patent, 1 generic authorized23 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
cenvacibart☆ Track2 live phase-3 studies: NCT07430956, NCT07626411Regeneron Pharmaceuticals
amrecibart☆ Track1 live phase-3 study: NCT07430956Regeneron Pharmaceuticals
abelacimab☆ Track1 live phase-3 study: NCT07739888Novartis

The 3 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 9 Feb 2027 est.cenvacibart, amrecibart · Regeneron Pharmaceuticals · Phase 2 main aimvs apixabanNCT07175428 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation — primary endpoint: Incidence of any bleeding · 1,200 enrolled
  • May 2027 est.AP31969 · Acesion Pharma · Phase 2 main aimNCT07267949 Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation — primary endpoint: Atrial fibrillation burden · 200 enrolled
  • 30 Jun 2027 est.budiodarone · Xyra, LLC · Phase 2 main aimNCT07792239 Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation — primary endpoint: Proportion of participants that have no long episodes of atrial fibrillation (LEAF) in the final month of treatment · 100 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Atrial Fibrillation studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Factor Xa inhibitors 21 open · Potassium channel blockers 10 open · SGLT2 inhibitors 8 open · GLP-1 receptor agonists 7 open · Calcium channel blockers 4 open

Coming up

323studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger. 21 (3%) take children under 18. 1 (<1%) are for women only and 2 (<1%) for men only; 43 (7%) take healthy volunteers.

Recruiting studies that take each age, of 610
AgeWomenMen
1016 (3%)16 (3%)
18498 (82%)498 (82%)
30559 (92%)559 (92%)
40567 (93%)568 (93%)
50570 (93%)572 (94%)
65595 (98%)595 (98%)
75591 (97%)590 (97%)
85485 (80%)484 (79%)

Across all 4,016 studies, recruiting or not: 10% stop at 75 or younger and 2% at 65; 5% take children; <1% are for women only and <1% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Atrial Fibrillation studies take

Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 111 mo3–20 · 20 studies——
Phase 232 mo18–39 · 41 studies——
Phase 342 mo32–63 · 83 studies—56 mo32–73 · 62 studies
Phase 448 mo27–81 · 141 studies—53 mo28–81 · 129 studies
Interventional, no phase33 mo18–54 · 1,049 studies22 mo12–36 · 255 studies39 mo21–59 · 794 studies
Observational38 mo22–76 · 700 studies26 mo14–42 · 148 studies46 mo25–91 · 552 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered34

Show 29 more

Studies

Recruiting first, then most recently updated. Showing 50 of 4,016. Browse all 4,016 → or search them.